Weitz & Luxenberg co-founder Perry Weitz will co-chair the Cutting-Edge Issues in Asbestos Litigation Conference on March 11-12 at the Beverly Wilshire hotel in Beverly Hills, California. Mr. Weitz and two other W&L attorneys are also speaking at the event.
The two-day conference will cover various aspects of the top emerging trends in asbestos litigation, including an overview of the most significant developments from 2018, an examination of the leading factors that will drive the industry in 2019, and a discussion on national filing trends and statistics. Additionally, the conference will feature sessions on revisiting docket management in mass filing jurisdictions, DNA in the courtroom, talc litigation, in-house counsel and insurance perspectives, and jurisdictional updates from California, Illinois, Missouri, New York, and Pennsylvania.
Mr. Weitz will co-chair the conference with John D. Cooper, Lisa L. Oberg, and Timothy L. Krippner, all of whom had a role in hand-selecting this year’s agenda topics.
“Mesothelioma continues to be a major health problem for Americans, with studies showing that the national mesothelioma mortality rate is on the rise,” said Perry Weitz. “I look forward to the opportunity to discuss the latest developments and trends in asbestos litigation so that we can continue to fight on behalf of mesothelioma victims and their families.”
In addition to co-chairing the event, Mr. Weitz will deliver opening remarks and participate in panel discussions on Docket Management in Mass Filing Jurisdictions and Clearing the Logjam: Finding the Middle Ground for Mass Claim Resolution?
W&L Mesothelioma and Asbestos Practice Group Chair Charles M. Ferguson will also participate on a panel discussing the Top Emerging Trends in Asbestos Litigation, while Managing Attorney Lisa Nathanson Busch will participate in a panel entitled A Pragmatic Overview of Current Bankruptcy Trust Function and Impact in Tort Cases.
Weitz & Luxenberg has more than three decades of experience representing thousands of mesothelioma patients nationwide, helping them be awarded more than $8.5 billion in verdicts and settlements.